Single-dose respiratory mucosal delivery of next-generation viral-vectored COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
暂无分享,去创建一个
M. Jordana | Ramandeep Singh | Fuan Wang | A. Zhang | J. Ang | J. Bavananthasivam | B. Lichty | K. Mossman | M. Medina | M. Jeyanathan | S. Afkhami | F. Smaill | Z. Xing | Y. Wan | H. Stacey | J. Koenig | U. Sankar | A. Gillgrass | A. Zganiacz | M. D’Agostino | M. Miller | Allyssa Phelps | Art Marzok | A. Kang | Gluke Ye | Xiangqian Luo | Natallia Kazhdan | Y. Wan
[1] M. Jenkins,et al. Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity , 2021, Journal of Immunology.
[2] M. Beer,et al. CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 , 2021, Nature Communications.
[3] D. Fremont,et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters , 2021, Cell Reports.
[4] H. Schuitemaker,et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.
[5] William T. Harvey,et al. SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.
[6] M. Koopmans,et al. SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients , 2021, Science Immunology.
[7] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[8] D. Fremont,et al. An intranasal vaccine durably protects against SARS-CoV-2 variants in mice , 2021, bioRxiv.
[9] D. Moodley,et al. Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant , 2021, The New England journal of medicine.
[10] R. Rappuoli,et al. SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies , 2021, Nature Medicine.
[11] Ravindra K. Gupta. Will SARS-CoV-2 variants of concern affect the promise of vaccines? , 2021, Nature Reviews Immunology.
[12] Justin M. Richner,et al. A SARS CoV-2 nucleocapsid vaccine protects against distal viral dissemination , 2021, bioRxiv.
[13] H. Fennema,et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.
[14] F. Krammer. Correlates of protection from SARS-CoV-2 infection , 2021, The Lancet.
[15] J. Rini,et al. Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2 , 2021, bioRxiv.
[16] D. Montefiori,et al. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 , 2021, The New England journal of medicine.
[17] Adam S. Dingens,et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 , 2021, Cell Reports Medicine.
[18] H. Jäck,et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies , 2021, Cell.
[19] D. Fremont,et al. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques , 2021, Cell Reports Medicine.
[20] A. Iafrate,et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.
[21] D. Ho,et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.
[22] J. Teijaro,et al. COVID-19 vaccines: modes of immune activation and future challenges , 2021, Nature Reviews Immunology.
[23] D. Fremont,et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.
[24] C. Aschwanden. Five reasons why COVID herd immunity is probably impossible , 2021, Nature.
[25] R. Scheuermann,et al. Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees. , 2021, bioRxiv.
[26] Ramandeep Singh,et al. COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] H. Mouquet,et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies , 2021, Nature Medicine.
[28] Heidi Ledford,et al. How to redesign COVID vaccines so they protect against variants , 2021, Nature.
[29] Caitlin E. Mullarkey,et al. IgA potentiates NETosis in response to viral infection , 2021, Proceedings of the National Academy of Sciences.
[30] Helio T. Navarro,et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia , 2020, Nature.
[31] M. V. van Zelm,et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence , 2020, Science Immunology.
[32] G. Gao,et al. Viral targets for vaccines against COVID-19 , 2020, Nature reviews. Immunology.
[33] N. Escriou,et al. Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models , 2020, Cell Host & Microbe.
[34] L. Carter,et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19 , 2020, Cell.
[35] S. Perlman,et al. COVID-19 Treatments and Pathogenesis Including Anosmia in K18-hACE2 mice , 2020, Nature.
[36] H. van Bakel,et al. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City , 2020, Nature.
[37] D. O’Connor,et al. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models , 2020, Nature Reviews Immunology.
[38] M. Jeyanathan,et al. Airway Macrophages Mediate Mucosal Vaccine–Induced Trained Innate Immunity against Mycobacterium tuberculosis in Early Stages of Infection , 2020, The Journal of Immunology.
[39] Lisa E. Gralinski,et al. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice , 2020, Cell.
[40] D. Cummings,et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity , 2020, Nature Communications.
[41] Matthew S. Miller,et al. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects , 2020, Viruses.
[42] S. Cauchemez,et al. COVID-19 herd immunity: where are we? , 2020, Nature Reviews Immunology.
[43] P. Sopp,et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.
[44] Matthew S. Miller,et al. Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.
[45] Lisa E. Gralinski,et al. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2 , 2020, Cell.
[46] J. Ravetch,et al. The role of IgG Fc receptors in antibody-dependent enhancement , 2020, Nature Reviews Immunology.
[47] M. Chen,et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction , 2020, Nature Biotechnology.
[48] D. Altmann,et al. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection , 2020, Science Immunology.
[49] Amogelang R. Raphenya,et al. Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Emerging infectious diseases.
[50] C. Cunningham-Rundles,et al. A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.
[51] N. Lurie,et al. Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.
[52] J. Bavananthasivam,et al. Innate immune memory of tissue‐resident macrophages and trained innate immunity: Re‐vamping vaccine concept and strategies , 2020, Journal of leukocyte biology.
[53] A. Clayton,et al. Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice , 2019, Molecular therapy. Methods & clinical development.
[54] D. Farber,et al. Location, location, location: Tissue resident memory T cells in mice and humans , 2019, Science Immunology.
[55] J. Schertzer,et al. Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity , 2018, Cell.
[56] M. Jeyanathan,et al. New Tuberculosis Vaccine Strategies: Taking Aim at Un-Natural Immunity. , 2018, Trends in immunology.
[57] M. Jordana,et al. CXCR3 Signaling Is Required for Restricted Homing of Parenteral Tuberculosis Vaccine–Induced T Cells to Both the Lung Parenchyma and Airway , 2017, The Journal of Immunology.
[58] R. Baric,et al. Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses , 2016, Immunity.
[59] M. Jeyanathan,et al. Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments , 2015, European Respiratory Review.
[60] H. Ertl,et al. Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection , 2015, Mucosal Immunology.
[61] Alex K. Heer,et al. Alveolar Macrophages Are Essential for Protection from Respiratory Failure and Associated Morbidity following Influenza Virus Infection , 2014, PLoS pathogens.
[62] M. Jenkins,et al. Deletion and anergy of polyclonal B cells specific for ubiquitous membrane-bound self-antigen , 2012, The Journal of experimental medicine.
[63] I. M. Belyakov,et al. What Role Does the Route of Immunization Play in the Generation of Protective Immunity against Mucosal Pathogens? , 2009, The Journal of Immunology.
[64] S. Akira,et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. , 2007, Immunity.
[65] K. Überla,et al. Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies , 2007, Virology.
[66] P. Kozlowski,et al. Mucosal vaccines: the promise and the challenge , 2006, Nature Reviews Immunology.
[67] Z. Xing,et al. Mechanisms of Mucosal and Parenteral Tuberculosis Vaccinations: Adenoviral-Based Mucosal Immunization Preferentially Elicits Sustained Accumulation of Immune Protective CD4 and CD8 T Cells within the Airway Lumen1 , 2005, The Journal of Immunology.
[68] Z. Xing,et al. Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis1 , 2004, The Journal of Immunology.